Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Roche

Do Teenagers On Isotretinoin Actually Understand The Risks They’re Signing Off On?

For many teenagers, this acne medication is life-changing. For a small number of users, however, it brings something they never expected: depression and panic. The debate over whether patients are being warned properly has never really gone away. While most finish treatment without severe psychiatric problems, some users say the…

Bored Panda

Behind the patient campaigns, the pharma giants profiting from public pressure

Comment: Auckland’s Forbidden Pharmacy highlights 200 unfunded drugs as patient advocates push politicians for more money.Listening to them, you’d think NZ was a cheapskate in funding healthcare – but in fact, it’s in the top half of the OECD. Jonathan Milne reports.

Newsroom.co.nz

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Approves First Generic Baloxavir (Xofluza): Single-Dose Flu Treatment Now Available at Generic Price

FDA approved the first generic baloxavir marboxil (Xofluza) on June 17, 2026. Norwich Pharmaceuticals developed the single-dose flu treatment for patients 5 and older.

Medical Daily

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls

The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.

Fortune

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma

MarketBeat

Roche gets European approval for Alzheimer’s diagnosis blood test

Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnostic methods.

Euronews

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

MarketBeat

US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes

US drug price cuts may push up the cost of new medicines in Switzerland, Roche's CEO warns.

International Business Times

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Benzinga

Simple blood test gets green light by FDA to improve early detection of Alzheimer’s disease

Millions of Americans are living with Alzheimer’s and hundreds of thousands are diagnosed each year

The Independent UK

Trump’s latest tariff threat raises concerns for UK pharmaceuticals

Britain will ‘actively engage’ with US over possible 100% duties, with truck and cabinet makers also in firing line

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

Benzinga

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

On Thursday, Roche Holdings AG (OTC:RHHBY) agreed to acquire 89bio, Inc. (NASDAQ:ETNB) for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases.

The Independent UK

‘Game-changing’ new Alzheimer’s drug could slow progression of disease

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK

The Independent UK

New antibiotic that could save millions of lives enters final testing

IN FULL

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing

It is hoped that the drug zosurabalpin will be approved by the end of the decade

MarketBeat

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

The Guardian - UK

US drug firm Merck says existing Trump tariffs will cost it $200m this year

Company’s forecast does not account for threatened ‘major’ tariff that could also be levied on pharmaceutical imports

Euronews

Swiss pharma giant Roche pledges to invest €47 billion in the US

The investment plans include new R&D sites in four US states and creating more than 12,000 jobs, according to the Swiss pharmaceutical company.

Latin Times

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Fortune

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

The Guardian - UK

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.